Protagonist Therapeutics, Inc. (NASDAQ:PTGX) Given Average Recommendation of "Moderate Buy" by Brokerages

Key Points

• Analysts remain broadly bullish: Eighteen brokerages give Protagonist Therapeutics a consensus “Moderate Buy” rating, including 15 buys and one strong buy. The average 12-month price target is $137.86, although recent targets range as high as $186.
• Shares have surged and results exceeded expectations: PTGX opened at $152.01, near its 12-month high of $152.70, while quarterly earnings of $2.29 per share and revenue of $213.47 million slightly beat consensus estimates. Revenue increased 3,746.8% year over year.
• Insiders have been selling while institutions maintain strong ownership: Insiders sold 127,000 shares worth about $17.8 million during the past quarter, including substantial sales by the CEO under a pre-arranged Rule 10b5-1 plan. Institutional investors own 98.63% of the company and several firms recently increased their positions.

Shares of Protagonist Therapeutics, Inc. (NASDAQ:PTGX - Get Free Report) have been given an average rating of "Moderate Buy" by the eighteen research firms that are currently covering the stock, MarketBeat Ratings reports. Two investment analysts have rated the stock with a hold rating, fifteen have assigned a buy rating and one has assigned a strong buy rating to the company. The average twelve-month price target among analysts that have issued ratings on the stock in the last year is $137.8571.

Several research analysts have recently commented on PTGX shares. Weiss Ratings raised shares of Protagonist Therapeutics from a "sell (d+)" rating to a "hold (c+)" rating in a research note on Tuesday. Citigroup upped their target price on shares of Protagonist Therapeutics from $130.00 to $175.00 and gave the stock a "buy" rating in a research note on Thursday, August 6th. UBS Group upgraded shares of Protagonist Therapeutics to a "buy" rating in a report on Monday. The Goldman Sachs Group raised shares of Protagonist Therapeutics from a "neutral" rating to a "buy" rating and raised their price target for the company from $110.00 to $186.00 in a research report on Monday. Finally, Wolfe Research assumed coverage on shares of Protagonist Therapeutics in a research note on Thursday, May 21st. They issued an "outperform" rating and a $135.00 price target for the company.

Insiders Place Their Bets

In other Protagonist Therapeutics news, Director William D. Waddill sold 9,000 shares of the stock in a transaction dated Tuesday, June 23rd. The stock was sold at an average price of $117.94, for a total value of $1,061,460.00. Following the sale, the director owned 7,825 shares of the company's stock, valued at $922,880.50. This trade represents a 53.49% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CEO Dinesh V. Ph D. Patel sold 65,761 shares of Protagonist Therapeutics stock in a transaction dated Monday, August 10th. The shares were sold at an average price of $149.11, for a total value of $9,805,622.71. Following the completion of the transaction, the chief executive officer owned 523,478 shares of the company's stock, valued at $78,055,804.58. The trade was a 11.16% decrease in their position. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last quarter, insiders sold 127,000 shares of company stock valued at $17,818,139. 5.19% of the stock is currently owned by company insiders.

Institutional Inflows and Outflows

Institutional investors have recently added to or reduced their stakes in the company. Royal Bank of Canada increased its position in shares of Protagonist Therapeutics by 30.6% in the 1st quarter. Royal Bank of Canada now owns 9,964 shares of the company's stock valued at $482,000 after purchasing an additional 2,334 shares during the last quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. lifted its position in shares of Protagonist Therapeutics by 0.9% during the 1st quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 37,403 shares of the company's stock worth $1,810,000 after purchasing an additional 348 shares during the last quarter. Millennium Management LLC lifted its position in shares of Protagonist Therapeutics by 283.6% during the 1st quarter. Millennium Management LLC now owns 134,269 shares of the company's stock worth $6,493,000 after purchasing an additional 99,269 shares during the last quarter. Arrowstreet Capital Limited Partnership acquired a new position in shares of Protagonist Therapeutics during the second quarter worth $987,000. Finally, Guggenheim Capital LLC grew its stake in shares of Protagonist Therapeutics by 1.6% during the second quarter. Guggenheim Capital LLC now owns 19,208 shares of the company's stock worth $1,062,000 after purchasing an additional 303 shares in the last quarter. Hedge funds and other institutional investors own 98.63% of the company's stock.

Key Stories Impacting Protagonist Therapeutics

Here are the key news stories impacting Protagonist Therapeutics this week:

• Positive Sentiment: An analyst article maintained a “Strong Buy” view, citing FDA approval of ICOTYDE for moderate-to-severe plaque psoriasis, attractive partnership economics and additional pipeline opportunities. Investors are also watching the FDA’s expected August 2026 Priority Review decision for rusfertide, which could lead to significant milestones and royalty payments from Takeda. The company plans to begin a Phase 2b study of oral IL-17 antagonist PN-881 in the first quarter of 2027. Protagonist Therapeutics: Strong Buy—ICOTYDE FDA Approval and PN-881 Advancement
• Positive Sentiment: A psoriasis-focused stock roundup included PTGX among companies offering exposure to approved therapies, late-stage candidates and earlier-stage psoriasis programs. This reinforces investor interest in Protagonist’s inflammatory-disease pipeline, although the article does not provide a new company-specific catalyst. 4 Psoriasis Drug Stocks to Watch During Psoriasis Awareness Month 2026
• Neutral Sentiment: Reported short interest was listed at zero shares, unchanged from the prior period, with a zero-day short-interest ratio. Because the figures appear anomalous, they provide little meaningful indication of near-term short-covering or bearish pressure.
• Negative Sentiment: CEO Dinesh V. Patel sold a combined 100,000 shares for approximately $14.9 million in transactions dated August 10 and 11. The sales reduced his reported ownership, which can pressure sentiment; however, both transactions were executed under a pre-arranged Rule 10b5-1 trading plan, making them less indicative of a fresh change in management’s outlook. SEC insider transaction filing

Protagonist Therapeutics Trading Up 2.5%

PTGX opened at $152.01 on Thursday. The stock's 50-day moving average price is $127.64 and its 200 day moving average price is $106.78. Protagonist Therapeutics has a 12-month low of $54.18 and a 12-month high of $152.70. The firm has a market cap of $9.84 billion, a price-to-earnings ratio of 147.58 and a beta of 1.78.

Protagonist Therapeutics (NASDAQ:PTGX - Get Free Report) last released its earnings results on Wednesday, August 5th. The company reported $2.29 earnings per share for the quarter, beating the consensus estimate of $2.27 by $0.02. The company had revenue of $213.47 million during the quarter, compared to the consensus estimate of $212.03 million. Protagonist Therapeutics had a return on equity of 12.03% and a net margin of 29.40%.Protagonist Therapeutics's quarterly revenue was up 3746.8% on a year-over-year basis. On average, research analysts forecast that Protagonist Therapeutics will post 4.02 earnings per share for the current year.

About Protagonist Therapeutics

Protagonist Therapeutics, Inc NASDAQ: PTGX is a clinical-stage biopharmaceutical company focused on the development of novel, orally administered peptide-based therapies for immune-mediated and other serious diseases. The company leverages its proprietary Peptide 2.0 platform to design peptides that target G protein–coupled receptors and cytokine receptors, with the goal of combining the potency of biologics with the convenience of oral administration. Protagonist's approach aims to address unmet medical needs in areas where injectable therapies have been the standard of care.

Among its lead programs is PTG-100, an oral α4β7 integrin antagonist intended to block leukocyte migration to the gut in ulcerative colitis and Crohn's disease.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source